Form 8-K - Current report:
SEC Accession No. 0001193125-22-023502
Filing Date
2022-01-31
Accepted
2022-01-31 17:16:03
Documents
12
Period of Report
2022-01-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d299821d8k.htm   iXBRL 8-K 33596
  Complete submission text file 0001193125-22-023502.txt   159397

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA elym-20220127.xsd EX-101.SCH 2844
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE elym-20220127_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elym-20220127_pre.xml EX-101.PRE 11699
6 EXTRACTED XBRL INSTANCE DOCUMENT d299821d8k_htm.xml XML 3482
Mailing Address 23515 NE NOVELTY HILL ROAD SUITE B221 #125 REDMOND WA 98053
Business Address 23515 NE NOVELTY HILL ROAD SUITE B221 #125 REDMOND WA 98053 425-276-2300
Eliem Therapeutics, Inc. (Filer) CIK: 0001768446 (see all company filings)

EIN.: 832273741 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40708 | Film No.: 22575049
SIC: 2834 Pharmaceutical Preparations